Several pharmaceutical stocks fell precipitously on news that the US Department of Justice could punish companies participating in collusion over generics pricing. Allergan (AGN), Teva (TEVA), Mylan (MYL), Endo (ENDP) and Valeant (VRX) are each down on the news, with Endo down over 15%. Some 12 drug makers will likely be charged by the end of the year.iShares Biotechnology ETF (IBB), the most prominent biotech ETF on the market, has been down some 24% over the past year and down 38% since June 2015.